Cargando…

Engineered soluble ACE2 receptor: Responding to change with change

SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangyao, Qian, Kewen, Zhang, Shuyi, Fu, Wenyan, Zhao, Jian, Lei, Changhai, Hu, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891289/
https://www.ncbi.nlm.nih.gov/pubmed/36741399
http://dx.doi.org/10.3389/fimmu.2022.1084331
_version_ 1784881110691348480
author Li, Guangyao
Qian, Kewen
Zhang, Shuyi
Fu, Wenyan
Zhao, Jian
Lei, Changhai
Hu, Shi
author_facet Li, Guangyao
Qian, Kewen
Zhang, Shuyi
Fu, Wenyan
Zhao, Jian
Lei, Changhai
Hu, Shi
author_sort Li, Guangyao
collection PubMed
description SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that occurred early in the pandemic is gradually showing signs of slowing. While recombinant soluble ACE2, as an alternative therapy, has been modified by many engineering methods, both the safety and functional aspects are approaching maturity, and this therapy shows great potential for broadly neutralizing coronaviruses, but its progress in clinical development remains stalled. Therefore, there are still several key problems to be considered and solved for recombinant soluble ACE2 to be approved as a clinical treatment as soon as possible.
format Online
Article
Text
id pubmed-9891289
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98912892023-02-02 Engineered soluble ACE2 receptor: Responding to change with change Li, Guangyao Qian, Kewen Zhang, Shuyi Fu, Wenyan Zhao, Jian Lei, Changhai Hu, Shi Front Immunol Immunology SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that occurred early in the pandemic is gradually showing signs of slowing. While recombinant soluble ACE2, as an alternative therapy, has been modified by many engineering methods, both the safety and functional aspects are approaching maturity, and this therapy shows great potential for broadly neutralizing coronaviruses, but its progress in clinical development remains stalled. Therefore, there are still several key problems to be considered and solved for recombinant soluble ACE2 to be approved as a clinical treatment as soon as possible. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9891289/ /pubmed/36741399 http://dx.doi.org/10.3389/fimmu.2022.1084331 Text en Copyright © 2023 Li, Qian, Zhang, Fu, Zhao, Lei and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Guangyao
Qian, Kewen
Zhang, Shuyi
Fu, Wenyan
Zhao, Jian
Lei, Changhai
Hu, Shi
Engineered soluble ACE2 receptor: Responding to change with change
title Engineered soluble ACE2 receptor: Responding to change with change
title_full Engineered soluble ACE2 receptor: Responding to change with change
title_fullStr Engineered soluble ACE2 receptor: Responding to change with change
title_full_unstemmed Engineered soluble ACE2 receptor: Responding to change with change
title_short Engineered soluble ACE2 receptor: Responding to change with change
title_sort engineered soluble ace2 receptor: responding to change with change
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891289/
https://www.ncbi.nlm.nih.gov/pubmed/36741399
http://dx.doi.org/10.3389/fimmu.2022.1084331
work_keys_str_mv AT liguangyao engineeredsolubleace2receptorrespondingtochangewithchange
AT qiankewen engineeredsolubleace2receptorrespondingtochangewithchange
AT zhangshuyi engineeredsolubleace2receptorrespondingtochangewithchange
AT fuwenyan engineeredsolubleace2receptorrespondingtochangewithchange
AT zhaojian engineeredsolubleace2receptorrespondingtochangewithchange
AT leichanghai engineeredsolubleace2receptorrespondingtochangewithchange
AT hushi engineeredsolubleace2receptorrespondingtochangewithchange